ABEO Abeona Therapeutics Inc

Price (delayed)

$5.37

Market cap

$221.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.2

Enterprise value

$226.44M

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis ...

Highlights
The company's quick ratio rose by 33% QoQ
Abeona Therapeutics's net income has shrunk by 186% YoY and by 41% QoQ
Abeona Therapeutics's equity has shrunk by 160% QoQ and by 147% YoY

Key stats

What are the main financial stats of ABEO
Market
Shares outstanding
41.19M
Market cap
$221.17M
Enterprise value
$226.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
41.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.7
Earnings
Revenue
$3.5M
EBIT
-$75.39M
EBITDA
-$72.36M
Free cash flow
-$40.44M
Per share
EPS
-$3.2
Free cash flow per share
-$1.48
Book value per share
-$0.32
Revenue per share
$0.13
TBVPS
$2.74
Balance sheet
Total assets
$74.83M
Total liabilities
$83.71M
Debt
$23.17M
Equity
-$8.88M
Working capital
$54.84M
Liquidity
Debt to equity
-2.61
Current ratio
5.61
Quick ratio
5.46
Net debt/EBITDA
-0.07
Margins
EBITDA margin
-2,067.3%
Gross margin
100%
Net margin
-2,190.3%
Operating margin
-1,366.3%
Efficiency
Return on assets
-118.6%
Return on equity
-821.5%
Return on invested capital
-142.8%
Return on capital employed
-119.8%
Return on sales
-2,154%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
-2.54%
1 week
11.88%
1 month
17.51%
1 year
38.4%
YTD
7.19%
QTD
26.65%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$3.5M
Gross profit
$3.5M
Operating income
-$47.82M
Net income
-$76.66M
Gross margin
100%
Net margin
-2,190.3%
Abeona Therapeutics's net income has shrunk by 186% YoY and by 41% QoQ
ABEO's operating margin has soared by 65% YoY but it is down by 5% QoQ
Abeona Therapeutics's net margin has decreased by 41% QoQ but it has increased by 13% YoY
The operating income has decreased by 14% YoY and by 5% from the previous quarter

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
41.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
64.7
ABEO's EPS is down by 34% year-on-year and by 26% since the previous quarter
Abeona Therapeutics's equity has shrunk by 160% QoQ and by 147% YoY
ABEO's P/S is 26% above its last 4 quarters average of 34.2 and 22% above its 5-year quarterly average of 35.3

Efficiency

How efficient is Abeona Therapeutics business performance
Abeona Therapeutics's return on equity has shrunk by 146% QoQ
The company's return on invested capital has shrunk by 103% YoY and by 27% QoQ
The company's return on assets has shrunk by 95% YoY and by 30% QoQ
ABEO's ROS is down by 40% since the previous quarter but it is up by 12% year-on-year

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The company's total assets is 11% lower than its total liabilities
ABEO's total liabilities has soared by 142% YoY and by 70% QoQ
The company's total assets rose by 40% YoY and by 17% QoQ
Abeona Therapeutics's equity has shrunk by 160% QoQ and by 147% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.